Simplex Trading’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-47,345
| Closed | -$1.14M | – | 10421 |
|
|
2023
Q1 | $1.14M | Sell |
47,345
-2,035
| -4% | -$25.5K | ﹤0.01% | 2473 |
|
|
2022
Q4 | $521K | Buy |
49,380
+13,447
| +37% | +$109K | ﹤0.01% | 3122 |
|
|
2022
Q3 | $161K | Sell |
35,933
-12,433
| -26% | -$56.7K | ﹤0.01% | 4907 |
|
|
2022
Q2 | $193K | Buy |
48,366
+24,629
| +104% | +$117K | ﹤0.01% | 4660 |
|
|
2022
Q1 | $173K | Buy |
23,737
+12,724
| +116% | +$76.1K | ﹤0.01% | 5364 |
|
|
2021
Q4 | $61K | Sell |
11,013
-24,054
| -69% | -$153K | ﹤0.01% | 6993 |
|
|
2021
Q3 | $292K | Sell |
35,067
-4,110
| -10% | -$26.4K | ﹤0.01% | 4947 |
|
|
2021
Q2 | $330K | Buy |
+39,177
| New | +$316K | ﹤0.01% | 4818 |
|
|
2021
Q1 | – | Sell |
-7,392
| Closed | -$104K | – | 10390 |
|
|
2020
Q4 | $125K | Sell |
7,392
-8,450
| -53% | -$127K | ﹤0.01% | 5210 |
|
|
2020
Q3 | $203K | Buy |
15,842
+4,223
| +36% | +$53.3K | ﹤0.01% | 4096 |
|
|
2020
Q2 | $163K | Buy |
11,619
+4,827
| +71% | +$60.9K | ﹤0.01% | 4234 |
|
|
2020
Q1 | $62K | Sell |
6,792
-32
| -0.5% | -$412 | ﹤0.01% | 4911 |
|
|
2019
Q4 | $101K | Sell |
6,824
-111
| -2% | -$989 | ﹤0.01% | 4506 |
|
|
2019
Q3 | $47K | Buy |
+6,935
| New | +$70.1K | ﹤0.01% | 5077 |
|
Other funds holding PRVB
Simplex Trading's PRVB Position: Q2 2023 in Review
Simplex Trading sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 47,345 shares — an estimated $1.14M sold.
Simplex Trading first reported a position in PRVB in Q3 2019 and held it in 14 quarters. The position peaked at $1.14M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Simplex Trading reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Simplex Trading sold 47,345 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.14M.
- Simplex Trading first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 14 quarters.
- Simplex Trading's Provention Bio, Inc. Common Stock position peaked at $1.14M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.